Generalized Hypertrichosis Associated with the Use of Interleukin 17 Blockers in 2 Patients with Psoriasis

The document reports two cases of patients with plaque psoriasis who developed generalized hypertrichosis, an excessive hair growth condition, after being treated with interleukin (IL)-17A inhibitor therapy. The first case involved a 62-year-old man treated with secukinumab, who noticed thicker hair growth on his scalp, torso, and extremities after 20 months of therapy. The second case was a 39-year-old man treated with ixekizumab, who observed more pigmented hair and increased density of growth on his back and extremities after just 1 month of therapy. These cases suggest that IL-17A inhibitors, used for treating psoriasis, may lead to hypertrichosis. This side effect appears to be persistent and progressive if the therapy is not discontinued, but it is also reversible upon cessation of the drug. The document indicates that these are among the first reported cases of hypertrichosis associated with IL-17A inhibitors in the medical literature.